Published in Front Pharmacol on December 18, 2013
High Cardiorespiratory Fitness Is Negatively Associated with Daily Cortisol Output in Healthy Aging Men. PLoS One (2015) 0.77
Unique genetic loci identified for emotional behavior in control and chronic stress conditions. Front Behav Neurosci (2014) 0.76
New frontiers in the neuropsychopharmacology of mental illness. Front Pharmacol (2014) 0.76
Future Directions Concerning the Impact of Childhood and Adolescent Adversities in the Field of Men's Mental Health: The New York Declaration. Front Public Health (2015) 0.75
Quality of life predictors in patients with chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol (2017) 0.75
Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry (2005) 58.92
Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science (2003) 28.61
Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science (1996) 16.04
From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci (2008) 15.90
The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care (2001) 15.36
Serotonin transporter genetic variation and the response of the human amygdala. Science (2002) 9.31
Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry (2009) 8.74
A meta-analysis of cytokines in major depression. Biol Psychiatry (2009) 7.16
Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med (2009) 7.06
Physiology of microglia. Physiol Rev (2011) 6.99
The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature (2011) 6.71
Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. Psychosom Med (2004) 6.69
Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med (1990) 5.65
Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression. Neuron (2009) 5.20
Resting microglia directly monitor the functional state of synapses in vivo and determine the fate of ischemic terminals. J Neurosci (2009) 4.83
Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis. Diabetologia (2006) 4.71
Influence of child abuse on adult depression: moderation by the corticotropin-releasing hormone receptor gene. Arch Gen Psychiatry (2008) 4.65
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet (2006) 4.26
Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J (1987) 4.12
Depression as a predictor for coronary heart disease. a review and meta-analysis. Am J Prev Med (2002) 4.10
Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. Nat Rev Immunol (2006) 4.05
The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun (2001) 2.89
Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry (2002) 2.87
A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry (2013) 2.68
Depression in rheumatoid arthritis: a systematic review of the literature with meta-analysis. Psychosom Med (2002) 2.67
Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies. Am J Epidemiol (1980) 2.62
Cytokine-induced sickness behaviour: a neuroimmune response to activation of innate immunity. Eur J Pharmacol (2004) 2.60
Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflammation, sickness behavior, and anhedonia. J Neuroinflammation (2008) 2.53
Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. Brain Behav Immun (2005) 2.52
Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab (2009) 2.50
Role of stress in the pathogenesis of the metabolic syndrome. Psychoneuroendocrinology (2005) 2.47
Suicidal behavior and severe neuropsychiatric disorders following glucocorticoid therapy in primary care. Am J Psychiatry (2012) 2.47
Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol (2004) 2.45
The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry (2006) 2.44
A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatry (2007) 2.38
Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis. Mol Psychiatry (2011) 2.32
Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research. Psychosom Med (2011) 2.30
The effects of tryptophan depletion on mood and psychiatric symptoms. J Affect Disord (2001) 2.28
Depression and anxiety in people with inflammatory bowel disease. J Epidemiol Community Health (2001) 2.21
Enhancing versus suppressive effects of stress on immune function: implications for immunoprotection and immunopathology. Neuroimmunomodulation (2009) 2.17
The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology (2011) 2.15
How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br J Pharmacol (2006) 2.14
Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment. Biol Psychiatry (2003) 2.05
Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome. J Endocrinol (2008) 2.01
Major depressive disorder and hypothalamic-pituitary-adrenal axis activity: results from a large cohort study. Arch Gen Psychiatry (2009) 2.00
Stress generation in depression: A systematic review of the empirical literature and recommendations for future study. Clin Psychol Rev (2010) 1.99
IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry (2005) 1.98
Symptoms of depression as a risk factor for incident diabetes: findings from the National Health and Nutrition Examination Epidemiologic Follow-up Study, 1971-1992. Am J Epidemiol (2003) 1.95
Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia (2005) 1.93
Psychiatric adverse effects of corticosteroids. Mayo Clin Proc (2006) 1.88
The neuropsychiatric profile of Addison's disease: revisiting a forgotten phenomenon. J Neuropsychiatry Clin Neurosci (2006) 1.84
Major depression and activation of the inflammatory response system. Adv Exp Med Biol (1999) 1.84
Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest (2009) 1.82
Association between depressive symptoms and incidence of Crohn's disease and ulcerative colitis: results from the Nurses' Health Study. Clin Gastroenterol Hepatol (2012) 1.74
Depression in patients with coronary heart disease. Am J Med (2008) 1.73
Stress-induced elevation of glucocorticoids increases microglia proliferation through NMDA receptor activation. J Neuroimmunol (2005) 1.66
Genetic variation in cortico-amygdala serotonin function and risk for stress-related disease. Neurosci Biobehav Rev (2008) 1.65
The use of statins after a cardiac intervention is associated with reduced risk of subsequent depression: proof of concept for the inflammatory and oxidative hypotheses of depression? J Clin Psychiatry (2010) 1.64
Polymorphisms of the glucocorticoid receptor gene and major depression. Biol Psychiatry (2006) 1.62
Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Disord (2006) 1.58
Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy. J Clin Oncol (2000) 1.57
Prevalent and incident depression in community-dwelling elderly persons with diabetes mellitus: results from the ZARADEMP project. Diabetologia (2006) 1.55
Chronic unpredictable stress exacerbates lipopolysaccharide-induced activation of nuclear factor-kappaB in the frontal cortex and hippocampus via glucocorticoid secretion. J Neurosci (2006) 1.55
Attenuation of post-myocardial infarction depression in rats by n-3 fatty acids or probiotics starting after the onset of reperfusion. Br J Nutr (2012) 1.53
Endocrine and physiological changes in response to chronic corticosterone: a potential model of the metabolic syndrome in mouse. Endocrinology (2010) 1.52
Chronic stress alters the density and morphology of microglia in a subset of stress-responsive brain regions. Brain Behav Immun (2010) 1.49
Oxidative and antioxidative potential of brain microglial cells. Antioxid Redox Signal (2005) 1.48
Stress hormones: physiological stress and regulation of metabolism. Curr Opin Pharmacol (2009) 1.47
Major depression in late life is associated with both hypo- and hypercortisolemia. Biol Psychiatry (2007) 1.45
Functional biomarkers of depression: diagnosis, treatment, and pathophysiology. Neuropsychopharmacology (2011) 1.44
Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression - a potential biomarker? Biol Psychiatry (2006) 1.44
Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy. Brain Behav Immun (2004) 1.43
Convergent genetic modulation of the endocrine stress response involves polymorphic variations of 5-HTT, COMT and MAOA. Mol Psychiatry (2007) 1.43
Post-myocardial infarction depression. Evid Rep Technol Assess (Summ) (2005) 1.40
Cytokine activation of the HPA axis. Ann N Y Acad Sci (2000) 1.38
Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. BMC Med (2012) 1.37
Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. Psychoneuroendocrinology (2001) 1.37
Change in heart rate and heart rate variability during treatment for depression in patients with coronary heart disease. Psychosom Med (2001) 1.35
Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety (2009) 1.34
The impact of major depressive disorder on the short- and long-term outcome of Crohn's disease treatment with infliximab. Aliment Pharmacol Ther (2005) 1.34
The gut-brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Neuro Endocrinol Lett (2008) 1.33
Interaction of FKBP5 gene variants and adverse life events in predicting depression onset: results from a 10-year prospective community study. Am J Psychiatry (2011) 1.33
Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization. J Thorac Cardiovasc Surg (1994) 1.31
Neuroinflammatory response to lipopolysaccharide is exacerbated in mice genetically deficient in cyclooxygenase-2. J Neuroinflammation (2008) 1.30
Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J Clin Psychiatry (2012) 1.28
Moderation of adult depression by a polymorphism in the FKBP5 gene and childhood physical abuse in the general population. Neuropsychopharmacology (2011) 1.27
Socioeconomic determinants of disability and depression in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) (2011) 1.26
Depression in patients with rheumatoid arthritis: description, causes and mechanisms. Int J Clin Rheumtol (2011) 1.26
Intranasal immune challenge induces sex-dependent depressive-like behavior and cytokine expression in the brain. Neuropsychopharmacology (2007) 1.25
Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology (2004) 1.24
Glucocorticoids mediate stress-induced priming of microglial pro-inflammatory responses. Brain Behav Immun (2011) 1.23
Anxiety disorders: sex differences in prevalence, degree, and background, but gender-neutral treatment. Gend Med (2007) 1.22
Depression and anxiety in patients with rheumatoid arthritis: prevalence rates based on a comparison of the Depression, Anxiety and Stress Scale (DASS) and the hospital, Anxiety and Depression Scale (HADS). BMC Psychiatry (2012) 1.21
Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study. Int Clin Psychopharmacol (2006) 1.21
Are platelets the link between depression and ischemic heart disease? Am Heart J (2000) 1.19
Increased IgA and IgM responses against gut commensals in chronic depression: further evidence for increased bacterial translocation or leaky gut. J Affect Disord (2012) 1.18
Salivary cortisol levels in persons with and without different anxiety disorders. Psychosom Med (2010) 1.17
Psychiatric complications of treatment with corticosteroids: review with case report. Psychiatry Clin Neurosci (2011) 1.17
Chronic stress induced remodeling of the prefrontal cortex: structural re-organization of microglia and the inhibitory effect of minocycline. Cereb Cortex (2012) 1.15